Scotland’s plan to remobilise and redesign cancer services

The Government in Scotland has published a new plan to remobilise NHS cancer care to put the experience of patients at its heart. It will focus on improving services and ensuring that all patients have access to the best possible treatments. The coronavirus (COVID-19) pandemic has resulted in significant changes to the war cancer services […]

read more

First-line cabozantinib declined for a second time for use within NHS Scotland

Cabozantinib has been declined for a second time by the Scottish Medicines Consortium (SMC) for use within NHS Scotland for people with untreated, intermediate-risk or poor-risk advanced renal cell carcinoma (RCC). KCSN are extremely disappointed with this decision, which was made despite new anecdotal evidence as to the effectiveness of the drug against advanced RCC submitted in response to […]

read more

Cabozantinib declined for use within NHS Scotland for first-line treatment of advanced kidney cancer

We are very disappointed by the Scottish Medicines Consortium’s (SMC) decision not to recommend cabozantinib (Cabometyx) for use within NHS Scotland as a first-line treatment option for people with intermediate-risk or poor-risk advanced renal cell carcinoma (RCC). This is despite cabozantinib’s proven effectiveness at significantly extending progression-free survival in these patients compared to first-line sunitinib, as shown in the […]

read more

First-line tivozanib approved for use in NHS Scotland

We are delighted that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines, has published advice recommending tivozanib (Fotivda) as a new first-line treatment option for people with advanced renal cell carcinoma (RCC) for use within NHS Scotland. Tivozanib, a tyrosine kinase inhibitor, was accepted following consideration through the SMC’s Patient and Clinician Engagement (PACE) process, which is […]

read more

Nivolumab and cabozantinib accepted for use within NHS Scotland for advanced kidney cancer

The Scottish Medicines Consortium (SMC), which reviews newly licensed medicines, has published advice recommending two new kidney cancer medicines for routine use by NHS Scotland. Nivolumab (Opdivo), an immunotherapy for advanced kidney cancer, was accepted following consideration through the SMC’s Patient and Clinician Engagement (PACE) process, which is for medicines used at the end of life […]

read more

How Scotland plans to improve access to drugs for very rare diseases

The Scottish government has announced a set of measures aimed at giving it more flexibility in offering patient access to new expensive medicines for rare and end-of-life conditions.  Copyright 2016, Informa Business Intelligence, an Informa company. All rights reserved. The Scottish government has announced a set of measures aimed at giving it more flexibility in […]

read more
Showing all 6 results
  TOP